Studies have confirmed the existence of neurogenesis in the adult human brain, but whether newborn neurons bolster cognitive abilities remains controversial. In the February 25 Nature, scientists led ...

The notion that lithium might treat Alzheimer’s was revived last year when scientists reported that the brains of people and mice with amyloid pathology are deficient in the metal ion, and that the ...

Cerebral small vessel disease is an umbrella term for disorders that cause the brain’s small blood vessels to stiffen, narrow, clog, or leak. cSVD increases a person’s risk for stroke and is a common ...

As the brain’s fluid drainage systems become sluggish with age, troublemakers such as amyloid and tau aggregates start to build up. To flush out disease-causing detritus, neurosurgeons in China have ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain ...

At this year’s Alzheimer’s Association International Conference, held July 27-31 in Toronto, scientists introduced a plethora of new assays for biomarkers that could improve diagnosis and tracking of ...

The Dominantly Inherited Alzheimer Network has been at the vanguard of AD immunotherapy development, launching the first secondary and primary prevention trials, as well as the first study of ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...